CD19- or BCMA-targeted CTCT shows promising results in refractory MG, LES, IIM, and CIDP, offering sustained clinical improvement and a favorable safety profile. The gene discussed is CD19; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.